Eureka Forbes' Promoter Owes Dollars. Its Collateral Is Priced in Rupees.

A promoter loan taken in US dollars and secured on shares priced in rupees can demand more collateral even in a year when the share price goes nowhere — and nothing in the company's own accounts, or its credit rating, will tell you it is happening.

The fact that breaks the assumption

On 8 September, Eureka Forbes told the exchanges that CRISIL had upgraded its corporate credit rating from AA-/Positive to AA/Stable. Seven days later, on 15 September, its promoter pledged another 22,319,748 Eureka Forbes shares — 11.53% of the company — to the lenders on a holding-company loan.

That took the pledged share of Eureka Forbes to 51.00%, per the security trustee's own disclosure. Both statements are true at once, because they describe two different balance sheets. The rating is about the company. The pledge is about the loan its owner took against it.

One loan, followed

The promoter is Lunolux Limited, a Cyprus-registered company holding 121,041,730 Eureka Forbes shares, or 62.55%. On 1 May 2024 it signed a facility agreement with a lender group that, per the 22 September filings, now comprises Barclays Bank PLC and MUFG Bank's Hong Kong branch. The 7 August disclosure states what the money was for: refinancing an earlier term loan from 2021, plus fees and costs.

The security has been built up in layers:

This is why the 22 September headline — "additional pledge over its entire 62.55%" — is both technically right and uninformative. The whole stake has been encumbered since May 2024, through the non-disposal undertaking. What has moved is the pledged portion, from 33.57% to 51.00% in eight weeks. That is the same distinction our Vedanta piece on Sunday turned on: an encumbrance disclosure describes a contract, and you have to read which contract.

Now the loan itself. The reasons-for-encumbrance filing gives an "amount involved" for each pledge event, in dollars and in rupees:

And against the July row, the filing says: "Lunolux had not borrowed any additional amounts at the time of creation of the pledge created on July 28, 2026."

The mechanism

Work out what the filing's own numbers imply for the share price. The filing values each block of shares at the BSE closing price on the event date. Dividing value by shares gives about ₹449.80 a share on 7 May 2024 and about ₹456.45 on 28 July 2026. Over more than two years, the collateral's price moved about 1.5%.

The loan did not stand still. In rupees it went from ₹768.2 crore to ₹1,059.7 crore — up 37.9% — and the filing says nothing additional had been borrowed when the July pledge was created. Two things account for the rise:

1. The rupee. The filing's own exchange rates go from 83.50 to 95.80 per dollar, a 14.7% move. A dollar debt grows in rupee terms by exactly that much without anyone signing anything.
2. The dollar principal itself, which rose 20.2%, from USD 92 million to about USD 110.6 million. The filing does not explain this. Interest that accrues to the loan rather than being paid in cash is one common way a holding-company loan grows without a new drawing, but we have not seen the facility terms, and the filing does not say that is what happened.

Put the two sides together. Using the filing's own prices and loan amounts, the value of the pledged shares divided by the loan — our calculation, not a filed number — went like this:

• May 2024: 64,950,000 pledged shares × ₹449.80 = ₹2,921 crore, against ₹768 crore owed: 3.80x.
• 28 July 2026, before the top-up: the same shares × ₹456.45 = ₹2,965 crore, against ₹1,060 crore: 2.80x.
• After the July top-up: 76,368,729 shares = ₹3,486 crore: 3.29x.

The share price was up slightly. The cover fell by more than a quarter anyway. The whole erosion came from the liability side — the rupee and the principal — and the promoter answered it the only way a share-backed borrower can: with more shares.

September adds the second force. The September filing values the new tranche at the 18 September close, which works out to about ₹385.45 a share, 15.6% below the July figure. At that price the July pledge pool covered the loan about 2.73x, below where the July top-up had restored it. The trustee ties the September pledge to an amendment that extended the loan's tenor and increased its total commitment, not to a price test, and we do not know the facility's trigger. But the arithmetic is plain: after the new 22.3 million shares, cover on pledged shares stood at about 3.53x.

One more thing to know about the disclosures themselves. Each filing reports a "security cover" ratio: 7.087 in 2024, then 0.49 in July and 0.80 in September. They cannot be compared. The footnotes say the July and September ratios divide only that event's new shares by the entire loan, while the 2024 figure divides the whole 62.55% stake by the original loan. Read side by side without the footnotes, they suggest a collapse in cover that did not happen.

Where this breaks

The case against reading this as a warning is strong, and it should be stated in full.

The lenders are well covered. Even at ₹385.45, the whole 62.55% stake was worth about ₹4,666 crore on 18 September, 4.33x the loan. Pledging 51% is a large number, but at these prices it is nowhere near a forced sale.

The lenders just extended the loan. The September amendment extended the facility's tenor. Banks that expect trouble tend to shorten, not lengthen. The new money actually disbursed in September was small, USD 578,572.81, and the filing says it paid lender fees for the extension and transaction costs.

The company is not the borrower. Eureka Forbes does not owe this debt, and nothing in the filings says it guarantees it. CRISIL's upgrade concerns the company's own balance sheet and is not contradicted by anything here.

We do not know the terms. The facility's loan-to-value test, top-up trigger, interest rate and maturity are not in the filings. The trustee's word "top up" suggests a maintenance test exists, but we have not seen it.

This is one company. One promoter, one loan and three pledge events do not show a pattern across Indian holding-company finance, and we are not claiming one.

Why it costs the reader something

The risk this structure puts on a minority shareholder does not show up where investors usually look. It is not in Eureka Forbes' balance sheet, its debt ratios or its rating. It sits one level up, and it has two moving parts pulling the same way: a falling rupee grows the debt, and a falling share price shrinks the collateral. In a bad year for Indian equities both tend to arrive together, which is when more shares get pledged and when an enforced sale of a large block would do the most damage to the price every other holder gets.

For a company where the promoter holds 62.55%, that block is most of the float's future supply.

What to do with it

Three habits, all using public filings:

1. Read the trustee's disclosure, not just the promoter's. Lunolux notes that pledges made through the depository system did not require its own disclosure, and that the 22 September filing was made "out of abundant caution." The July top-up surfaced first in Catalyst Trusteeship's own filing on 30 July.
2. Track the "amount involved" line in rupees over time. It is the one number that tells you whether the debt behind the pledge is growing.
3. Divide it into the current value of the pledged shares, not the filing's ratio. The filed ratio may cover only the latest tranche.

On 7 May 2024, the pledged shares covered the loan 3.8 times over. By 28 July 2026, with the share price slightly higher, they covered it 2.8 times, and another 11.4 million shares had to go in. Nothing about Eureka Forbes the business caused that. The loan did — a principal that grew in dollars, measured in a currency that fell against them.

Educational research, not investment advice. Every filed figure above is drawn from the primary disclosures listed in the sources, read from the exchange copies on 23 September 2026 (two of them image-only, read via OCR and checked by eye against the page images). Per-share prices and cover ratios that use total pledged shares are our own calculations from the filings' stated values, labelled as such. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.